Quest Diagnostics Inc vs Uber Technologies Inc — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Uber Technologies Inc trades at $70 (market cap $139.81B). The key difference: Uber Technologies Inc is far larger — about 5.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.52% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Uber Technologies Inc for 88 Days on average.
| DGX | UBER | |
|---|---|---|
Market Cap | $25.06B | $139.81B |
Volume | 927,361 | 11,879,194 |
Sector | Health | Technology |
52-Week High | $247.45 | $99.72 |
52-Week Low | $173.49 | $65.94 |
Typical Hold Time | 56 Days | 88 Days |
Enterprise Value | $30.82B | $149.15B |
Dividend Yield | 1.52% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Uber (UBER) trades at $70.24, up 1.68% on the day, with a bearish technical signal from moving averages but strong fundamentals including 2025 revenue of $52.02 billion and net income of $10.05 billion. The company has beaten EPS estimates in two of the last three quarters and expanded its Uber Eats partnership with Costco to 47 states as of September 16, 2026. Operating cash flow grew to $10.10 billion in 2025, supporting a robust balance sheet with $6.98 billion in cash.
The outlook is positive given analyst consensus of a $104.72 price target and 82.54% buy ratings, though risks include a projected negative net cash flow in 2026 and competitive pressures from autonomous vehicle entrants. Upside is driven by earnings momentum and strategic expansions, while investor caution is warranted on execution and capital expenditure trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →